Tokyo, Japan

Yumiko Tsuruma


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 1983

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yumiko Tsuruma: Innovator in Antitumor Research

Introduction

Yumiko Tsuruma is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of novel uracil derivatives. Her work focuses on creating compounds that exhibit antitumor activity, which can be crucial in cancer treatment.

Latest Patents

Yumiko Tsuruma holds a patent for "Novel uracil derivatives, process for preparing the same." This patent includes a detailed description of uracil derivatives of a specific formula, wherein R₁, R₂, R₃, and X are defined in the documentation. The derivatives and their pharmaceutically acceptable salts are disclosed, along with the processes for their preparation. These compounds have demonstrated good antitumor activity, making them valuable for pharmaceutical compositions aimed at treating cancer.

Career Highlights

Yumiko Tsuruma is associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. Her innovative research has positioned her as a key figure in the development of new cancer therapies. With her expertise, she continues to contribute to advancements in the pharmaceutical industry.

Collaborations

Yumiko has collaborated with notable colleagues, including Kiyoshige Ochi and Katsuhito Miyamoto. These partnerships have enhanced her research efforts and have led to significant advancements in the field of antitumor preparations.

Conclusion

Yumiko Tsuruma's work in developing novel uracil derivatives showcases her dedication to advancing cancer treatment. Her contributions to the pharmaceutical industry are invaluable, and her innovative spirit continues to inspire future research in this critical area.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…